Related Experiment Video
Updated: Mar 1, 2026
09:01
Normothermic Ex Vivo Pancreas Perfusion for the Preservation of Pancreas Allografts before Transplantation
Published on: July 27, 2022
2.6K
Advances in pancreas transplantation
George W Burke1, Gaetano Ciancio, Hans W Sollinger
1Lillian Jean Kaplan Renal Transplantation Center, University of Miami/Jackson Memorial Medical Center, Miami, FL 33136, USA.
Transplantation
|June 18, 2004
Summary
Pancreatic transplantation outcomes have improved due to new procedures and immunosuppressive drugs like tacrolimus, enhancing graft survival. Further research into islet and xenotransplantation is recommended for type 1 diabetes and renal disease patients.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Pancreatic transplantation faced early challenges impacting success rates.
- Advancements in surgical techniques and immunosuppression are crucial for improving patient outcomes.
Purpose of the Study:
- To review the advancements in pancreatic transplantation over the past two decades.
- To highlight the impact of new procedures and immunosuppressive therapies on graft survival and rejection rates.
- To suggest future research directions for pancreatic transplantation.
Main Methods:
- Review of procedural improvements such as bladder drainage and human leukocyte antigen matching.
- Analysis of the introduction and impact of immunosuppressive agents: tacrolimus, mycophenolate mofetil, and corticosteroids.
- Evaluation of outcomes in pancreatic transplant recipients.
Main Results:
- Improved graft survival and reduced acute rejection rates attributed to newer immunosuppressive regimens.
- Tacrolimus and mycophenolate mofetil demonstrated better efficacy and lower nephrotoxicity compared to cyclosporine.
- Corticosteroid-sparing regimens contributed to decreased acute pancreas rejection.
Conclusions:
- Significant improvements in pancreatic transplantation outcomes have been achieved through procedural and therapeutic advancements.
- Current strategies have enhanced graft survival and reduced rejection, offering better options for patients.
- Further exploration of pancreatic islet transplantation and xenotransplantation is warranted for managing type 1 diabetes and end-stage renal disease.
